Pancragen
Also known as: Lys-Glu-Asp-Trp, KEDW, H-Lys-Glu-Asp-Trp-NH2, Lys-Glu-Asp-Trp-NH2, tetrapeptide pancragen
Synthetic short peptide / bioregulatory tetrapeptide
What it is
Pancragen is a synthetic peptide studied in animals and cell cultures for its potential to improve glucose tolerance and protect pancreatic function in aging. Research is limited to laboratory and animal models. No FDA-approved use; primarily studied in Russian longevity research with limited independent replication.
The scientific side
Pancragen (Lys-Glu-Asp-Trp-NH2) is a synthetic tetrapeptide investigated for pancreatic cytoprotective and geroprotective effects. In aged pancreatic cell cultures, it increases expression of differentiation transcription factors for acinar cells (Pdx1, Ptf1a) and islet cells (Pdx1, Pax6, Pax4, Foxa2, NKx2.2). It also stimulates expression of CXCL12 and Hoxa3 differentiation factors in a tissue-specific manner in pancreatic cells. At the molecular level in aged pancreatic cell cultures, it increases expression of matrix metalloproteinases MMP2 and MMP9, serotonin, glycoprotein CD79alpha, antiapoptotic protein Mcl1, and proliferation markers PCNA and Ki67, while decreasing expression of proapoptotic p53. In organotypic tissue culture, it stimulates reparative processes in pancreatic tissue explants at a concentration of 0.05 ng/ml. In animal models of experimental diabetes, it exerts hypoglycemic and endothelioprotective effects.
Class: Synthetic short peptide / bioregulatory tetrapeptide
Administration & storage
- Administration
- Intramuscular injection — non-human primate studies (PMID: 28509500)Intramuscular injection — non-human primate studies (PMID: 25946840)Intramuscular injection — rat studies (PMID: 18642713)Oral administration — rat studies (PMID: 18642713)
- Storage
- No storage conditions for Pancragen are described in the reviewed abstracts.
- Cautions
- Human pharmacokinetic and safety data are absent from the reviewed literature; all dose-finding and efficacy data come from animal studies or a single small human observational study.,The human study does not report adverse events or specify route/dose, precluding assessment of human safety profile.,Intramuscular injection carries inherent risks (infection, injection-site reactions); sterile technique is essential regardless of compound.,No data on drug interactions, long-term toxicity, or pharmacovigilance for Pancragen were identified in the reviewed abstracts.,Purity and formulation standards of commercially available preparations are not addressed in the reviewed literature.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Correction of age-related impaired glucose tolerance / insulin resistance in elderly individuals and non-human primates Mixed
- In 33 elderly patients with type 2 diabetes mellitus, pancragen significantly decreased fasting glucose levels, glucose levels during standard glucose tolerance test, and reduced plasma insulin and insulin resistance index. No changes were observed in the control group not receiving pancragen. PMID 22448364 Korkushko OV et al. Bulletin of experimental biology and medicine (2011)
- In old female rhesus monkeys (20–25 years), Pancragen (0.05 mg/animal/day IM for 10 days) decreased basal blood glucose levels and normalized insulin and C-peptide levels, suggesting restoration of disturbed glucose tolerance. Authors concluded Pancragen is effective and safe for correction of age-related endocrine pan PMID 28509500 Goncharova ND et al. Advances in gerontology (2015)
- In old female rhesus monkeys, Pancragen (50 µg/animal/day IM for 10 days) markedly increased the glucose disappearance rate and normalized plasma insulin and C-peptide dynamics after glucose administration. The recovering effect partially remained 3 weeks after discontinuation. PMID 25946840 Goncharova ND et al. Advances in gerontology (2014)
- Stimulation of pancreatic cell differentiation during ageing In vitro only
- Pancragen stimulated expression of differentiation factors (Pdx1, Ptf1a, Pax6, Pax4, Foxa2, NKx2.2) in both young and aged pancreatic cell cultures. Authors proposed this as a mechanism underlying anti-diabetic and anti-inflammatory effects. PMID 23486591 Khavinson VKh et al. Bulletin of experimental biology and medicine (2013)
- Pancragen tissue-specifically stimulated expression of CXCL12 and Hoxa3 differentiation factors in human embryonic pancreatic cells; the inducing effect was more pronounced in aged (late-passage) cultures, proposed as a geroprotective mechanism. PMID 22808515 Khavinson VKh et al. Bulletin of experimental biology and medicine (2012)
- Pancragen (H-Lys-Glu-Asp-Trp-NH2) increased expression of MMP2, MMP9, serotonin, CD79alpha, Mcl1, PCNA, and Ki67 and decreased p53 expression in aged human pancreatic cell cultures, suggesting activation of functional activity markers relevant to its clinical effects in elderly patients with type 2 diabetes. PMID 23734516 Khavinson VKh et al. Advances in gerontology (2012)
- Hypoglycemic and endothelioprotective effects in experimental diabetes mellitus Animal studies only
- In Wistar rats with streptozotocin-induced diabetes mellitus, oral pancragen produced a pronounced hypoglycemic effect during treatment. Intramuscular pancragen normalized adhesion of mesenteric capillary endothelium but did not modify capillary permeability. Authors described homeostatic and endothelioprotective effec PMID 18642713 Khavinson VKh et al. Bulletin of experimental biology and medicine (2007)
- Biological effects of Lys-Glu-Asp-Trp-NH2 were evaluated during ontogeny and in streptozotocin-induced diabetes mellitus (a model of rapid experimental aging) using metabolic parameters characterizing apoptosis in insulin-secreting cells and liver. PMID 21246099 Khavinson VKh et al. Bulletin of experimental biology and medicine (2010)
- Tissue-specific stimulation of reparative processes in pancreatic tissue (organotypic culture) In vitro only
- Pancragen at 0.05 ng/ml showed a stimulating effect on organotypic tissue culture of pancreatic explants from both young (3-week-old) and aged (18-month-old) rats compared to control explants. PMID 17152728 Zakutskiy AN et al. Advances in gerontology (2006)
Safety signals
- Authors of a non-human primate study described Pancragen as 'effective and safe' for correction of age-related endocrine pancreatic imbalance, but no formal safety/toxicology data were reported in the abstract. PMID 28509500
- Glimepiride comparator in the same primate study led to a more expressed and delayed hypoglycemic effect relative to Pancragen, suggesting Pancragen's glucose-lowering effect may be milder; risk of hypoglycemia was not explicitly quantified for Pancragen. PMID 28509500
Protocol
No community dose for Pancragen on record yet.
All studies (9)
- PMID 22448364 Mixed
Correction of age-related impaired glucose tolerance / insulin resistance in elderly individuals and - PMID 25946840 Mixed
Correction of age-related impaired glucose tolerance / insulin resistance in elderly individuals and - PMID 28509500 Mixed
Correction of age-related impaired glucose tolerance / insulin resistance in elderly individuals and - PMID 17152728 In vitro only
Tissue-specific stimulation of reparative processes in pancreatic tissue (organotypic culture) - PMID 18642713 Animal studies only
Hypoglycemic and endothelioprotective effects in experimental diabetes mellitus - PMID 21246099 Animal studies only
Hypoglycemic and endothelioprotective effects in experimental diabetes mellitus - PMID 22808515 In vitro only
Stimulation of pancreatic cell differentiation during ageing - PMID 23486591 In vitro only
Stimulation of pancreatic cell differentiation during ageing - PMID 23734516 In vitro only
Stimulation of pancreatic cell differentiation during ageing
Frequently asked
What is Pancragen and what is it used for?
Pancragen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Trp-NH2. Published research has investigated it primarily for: (1) correcting age-related impaired glucose tolerance and insulin resistance in elderly humans and old non-human primates (PMID 28509500; PMID 25946840); (2) stimulating pancreatic cell differentiation markers in aged cell cultures (PMID 23486591; PMID 22808515); and (3) hypoglycemic and endothelioprotective effects in rat models of experimental diabetes. It is not approved as a medicine by any regulatory agency according to the reviewed literature.
What dose of Pancragen should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: animal studies used 0.05 mg/animal/day or 50 µg/animal/day intramuscularly for 10 days in rhesus monkeys (PMID 28509500; PMID 25946840). The one human study did not specify dose or route. No human dose-finding or pharmacokinetic studies were identified in the reviewed literature.
Can Pancragen help with type 2 diabetes?
Preclinical and limited human research has explored this. In one study of 33 elderly patients with type 2 diabetes mellitus, Pancragen significantly decreased fasting glucose and insulin resistance index compared to an untreated control group. Animal studies in old rhesus monkeys also showed normalization of glucose tolerance and insulin/C-peptide dynamics (PMID 28509500; PMID 25946840), and rat studies demonstrated hypoglycemic effects. However, large-scale randomized controlled trials in humans have not been reported in the reviewed literature. I can't suggest treatments for medical conditions — please speak with a licensed healthcare provider.
How is Pancragen administered — is it taken orally or by injection?
In the reviewed published studies, Pancragen has been administered by intramuscular injection in non-human primate studies (PMID 28509500; PMID 25946840) and by both oral and intramuscular routes in rat studies. The human study does not specify the route of administration. No reconstitution or preparation details were reported in the reviewed abstracts.
What are the known side effects or risks of Pancragen?
The reviewed literature does not include formal safety or toxicology studies for Pancragen. One non-human primate study described it as 'effective and safe' without reporting adverse event data. No human adverse event data, contraindications, or drug interaction information were identified in the reviewed abstracts. The absence of reported side effects should not be interpreted as confirmation of safety — I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly.
Can I stack Pancragen with other peptides or diabetes medications?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Pancragen was compared to glimepiride (a sulfonylurea) in separate arms of a non-human primate study, but no combination data were reported. No stacking or combination protocols appear in the reviewed literature.
Where can I buy Pancragen?
I don't recommend vendors or sources. Please consult a licensed provider.
Is Pancragen approved by the FDA or other regulatory agencies?
The reviewed literature does not state the regulatory status of Pancragen with any regulatory authority (FDA, Health Canada, EMA, or WADA). This requires manual verification with the relevant regulatory agencies.
How does Pancragen work mechanistically?
Based on in vitro and animal studies in the reviewed literature, Pancragen has been reported to: (1) stimulate expression of transcription factors controlling differentiation of acinar (Pdx1, Ptf1a) and islet (Pdx1, Pax6, Pax4, Foxa2, NKx2.2) pancreatic cells in aged cell cultures; (2) tissue-specifically stimulate CXCL12 and Hoxa3 differentiation markers in pancreatic cells; (3) increase expression of antiapoptotic protein Mcl1 and proliferation markers PCNA and Ki67 while reducing proapoptotic p53 in aged pancreatic cell cultures; and (4) exert hypoglycemic and endothelioprotective effects in streptozotocin-diabetic rats. These mechanisms have not been confirmed in controlled human trials.
Is there human clinical trial data for Pancragen?
The reviewed literature includes one human study: an observational study of 30 healthy older persons and 33 elderly patients with type 2 diabetes mellitus, in which pancragen significantly reduced fasting glucose, glucose during tolerance testing, and insulin resistance index in the diabetes group. Dose, route, and duration were not specified in the abstract. No randomized controlled trials in humans were identified in the reviewed abstracts.